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ABSTRACT
Introduction: Exenatide is gradually released
from exenatide once weekly (QW)
microspheres, and at steady state, consistently
controls glycated hemoglobin (HbA1c) in
patients with type 2 diabetes (T2D). This post
hoc analysis examined the timing to onset of
clinical responses and their correlations with
exenatide concentrations after initiation of
exenatide QW in patients with T2D.
Methods: Trial data were retrospectively
analyzed to explore the early clinical responses
to exenatide QW, including the relationship of
exenatide concentration with its effects on
efficacy [fasting plasma glucose (FPG), HbA1c,
and body weight] and tolerability (nausea and
vomiting). Exenatide QW efficacy and
tolerability data were from DURATION-5, a
24-week, randomized, comparator-controlled
trial [intent-to-treat (ITT) population].
Exenatide concentrations were measured in a
patient subset (pharmacokinetic population).
Results: In the ITT (n = 129)/pharmacokinetic
(n = 72) populations, baseline FPG, HbA1c, and
body weight were 173/173 mg/dL, 8.5%/8.4%,
and 97/98 kg, respectively. Exenatide
concentrations gradually increased until
reaching steady state at week 8. By week 4, the
FPG reduction (-32.4 mg/dL) was 94% of the
week 24 reduction (-34.6 mg/dL). Reductions
in HbA1c began by week 4 (-0.6%) and
stabilized by week 14 (week 24: -1.6%).
Weight reduction at week 4 was -0.7 kg and
decreased further (week 24: -2.3 kg). Peak
nausea (7.2%) and vomiting (2.4%) occurred
at weeks 6–8, declining thereafter.
Conclusion: Clinically relevant responses to
exenatide QW were evident by week 4, after
exenatide concentration passed the therapeutic
threshold but before steady state was achieved.
Trial Registration: ClinicalTrials.gov identifier:
NCT00877890.
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INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease
necessitating long-term, individualized
treatment. Challenges associated with some
treatments include weight gain, risk of
hypoglycemia, gastrointestinal side effects, and
rapid loss of glycemic control [1–3]. Other
factors considered by physicians and patients
may include mode of administration, frequency
of dosing, and initial timing of therapeutic
response, particularly for patients with
symptomatic hyperglycemia.
The glucagon-like peptide-1 receptor agonist
(GLP-1RA) exenatide improves glycemic control
and reduces weight, with a low risk of
hypoglycemia when taken without
concomitant sulfonylureas or insulin, but an
increased risk of gastrointestinal events [4]. The
once weekly (QW) formulation has
demonstrated sustained glycemic control and
is dosed infrequently [5], but the initial rate of
therapeutic response has been questioned.
Exenatide acts through multiple mechanisms
of action, including stimulating insulin
secretion in a glucose-dependent manner,
suppressing glucagon secretion in a
glucose-dependent manner, slowing gastric
emptying, reducing food intake, and
promoting satiety [4]. Dispersing exenatide in
poly-(D,L-lactide-co-glycolide [PLG]) polymer
microspheres—a biodegradable polymer—
allows for the continuous release of exenatide
with regular QW therapy [6]. Exenatide is
primarily released through diffusion and
erosion of the microspheres. With regular
dosing, plasma concentrations of exenatide
QW increase gradually to steady state in
approximately 6–8 weeks [7–10]; however,
treatment response may begin earlier, when
concentrations surpass the therapeutic
threshold [9].
The clinical development program for
exenatide QW consisted of six pivotal phase 3
studies: the Diabetes Therapy Utilization:
Researching Changes in A1C, Weight and
Other Factors through Intervention with
Exenatide Once Weekly (DURATION) trials.
Data from DURATION-5 were used in this post
hoc analysis [11], in which exenatide
concentrations and clinical responses were
measured for up to 24 weeks.
This analysis examined the relationships
between exenatide concentrations and clinical
responses to inform physician and patient
expectations of exenatide QW therapy for
treatment of T2D.
METHODS
Details of the DURATION-5 (ClinicalTrials.gov
identifier: NCT00877890) study design were
previously published [11]. Briefly, patients
with T2D aged C18 years who were treated for
C2 months with diet and exercise alone or with
a stable, maximally effective regimen of
metformin, sulfonylurea, thiazolidinedione, or
a combination of these medications and had a
glycated hemoglobin (HbA1c) of 7.1–11.0%,
fasting plasma glucose (FPG)\280 mg/dL, and
a body mass index of 25–45 kg/m2 were
included in the trial. Patients were randomized
to receive exenatide QW 2.0 mg subcutaneously
(SC) for 24 weeks (n = 129) or exenatide twice
daily (BID) 5 lg SC for 4 weeks followed by
exenatide BID 10 lg SC for 20 weeks (n = 123).
Only patients treated with exenatide QW were
included in this post hoc analysis. This article is
based on a previously conducted study and does
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not involve any new studies of human or
animal subjects performed by any of the
authors.
FPG, HbA1c, and body weight were
measured at weeks 1 (body weight only), 4, 8,
14, 20, and 24 in the intent-to-treat (ITT)
population consisting of all randomized
patients who received C1 dose of study
medication.
Exenatide concentration was determined by
a validated immunoenzymetric assay [9] in a
subset of patients in the ITT population, which
was designated the pharmacokinetic
(PK)-evaluable population, at baseline, at
weeks 4, 8, 14, and 20 (prior to administration
of the next dose of study medication), and at
study termination (week 24).
Nausea and vomiting adverse events (AEs)
were self-reported at all office visits and
categorized according to the Medical Dictionary
for Regulatory Activities (MedDRA) version 12.0
in the ITT population.
Statistical Analyses
Demographics and baseline characteristics were
reported descriptively. Because exenatide
concentrations were not normally distributed,
exenatide concentration was calculated as the
geometric mean ± standard error (SE). FPG was
reported in mg/dL [conversion factor to SI units
(mmol/L) = 0.0555]. The least-squares (LS)
mean ± SE changes from baseline for FPG and
HbA1c were calculated using an analysis of
variance model based on a general linear model
including factors for treatment group, HbA1c
stratum (\9.0% or C9.0%), and concomitant
sulfonylurea use at screening. The LS mean ± SE
change from baseline in body weight was
analyzed using a general linear model
including factors for treatment group, baseline
HbA1c stratum, concomitant sulfonylurea use
at screening, and baseline body weight. Missing
post-baseline values up to week 24 were
imputed using the last observation carried
forward approach. The statistical analyses were
performed using SAS version 9.2 (SAS Institute,
Cary, NC, USA).
A subanalysis examined mean (± standard
deviation) changes from baseline in FPG,
HbA1c, and body weight among patients who
had nausea AEs versus those without nausea
(ITT population).
RESULTS
Baseline demographics and characteristics were
generally well-matched between patients in the
ITT (n = 129) and PK-evaluable (n = 72)
populations, with small differences in age and
race (Table 1). In the ITT population, 20
patients (15.5%) treated with exenatide QW
withdrew during the study (withdrawal of
consent, n = 6; AE, n = 6; lost to follow-up,
n = 5; loss of glucose control, n = 3) [11].
Mean exenatide concentrations with
exenatide QW treatment gradually increased
until reaching steady state at approximately
8 weeks (PK-evaluable population; Fig. 1). In the
ITT population, reductions in FPG were
observed at 4 weeks, with further reductions at
8 weeks that plateaued thereafter. By week 4,
when exenatide concentrations were 31% of the
peak concentration, the FPG reduction
(-32.4 ± 4.3 mg/dL) was equivalent to 94% of
the week 24 reduction at steady state
(-34.6 ± 4.9 mg/dL). A reduction in HbA1c of
-0.6% ± 0.1% occurred at week 4, and change
in HbA1c plateaued by week 14. At week 24, the
reduction in HbA1c was -1.6% ± 0.1%. Weight
loss occurred at week 4 (-0.7 ± 0.2 kg), and
weight continued to decrease with treatment
(week 24: -2.3 ± 0.4 kg).
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Exenatide QW was generally well tolerated,
with no discontinuations due to nausea or
vomiting [11]. Reductions in FPG and HbA1c
were similar among patients with and without
nausea although weight loss was numerically
greater in patients with nausea (difference of
0.7 kg; ITT population; Table 2). Nausea and
vomiting decreased over the 24-week treatment
period (Fig. 2). The incidence of nausea peaked
at week 6 (7.2%) and that of vomiting at week 8
(2.4%), declining thereafter.
DISCUSSION
Physicians and patients may be interested to
know when novel long-acting therapies, such as
the GLP-1RA exenatide QW, become effective
and when maximum efficacy is achieved. This
post hoc analysis demonstrated that glycemic
control from exenatide QW begins before
steady state concentrations are achieved, with
near-maximal FPG reductions and clinically
relevant HbA1c reductions within 4 weeks and
near-maximal HbA1c reductions by 14 weeks.
In this study, measured plasma exenatide
concentrations progressively increased to steady
state at week 8. Similarly, reports on the PK and
pharmacodynamics of exenatide QW among
patients with T2D in the United States, China,
and Japan showed exenatide concentrations
reaching steady state after 6–8 weeks of weekly
dosing [7–10].
Consistent with multiple mechanisms of
action for exenatide, multiple relationships of
exenatide exposure with clinical responses were
demonstrated. FPG reduction was observed
Table 1 Baseline demographics and characteristics
Characteristics Exenatide QW
ITT population (n5 129) PK-evaluable population (n5 72)
Male, n (%) 77 (59.7) 45 (62.5)
Age at consent, years 56 ± 11 59 ± 10
Race/ethnicity, n (%)
White 81 (62.8) 50 (69.4)
Hispanic 37 (28.7) 14 (19.4)
Black 6 (4.7) 4 (5.6)
Asian 5 (3.9) 4 (5.6)
Weight, kg 97.0 ± 20.7 98.3 ± 22.1
BMI, kg/m2 33.6 ± 5.5 33.7 ± 5.7
HbA1c, %a 8.5 ± 1.1 8.4 ± 1.1
FPG, mg/dL 173 ± 47 173 ± 50
Duration of diabetes, years 7 ± 5 8 ± 6
Data are mean ± standard deviation unless otherwise noted
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, ITT intent-to-treat, PK pharmacokinetic,
QW once weekly
a One patient had missing baseline HbA1c; ITT population, n = 128; PK-evaluable population, n = 71
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most rapidly (at week 4—the earliest time point
measured), as the PK threshold for FPG lowering
(*50 pg/mL) [12] is typically reached at 2 weeks
[9]. A recent post hoc analysis of pooled data
from 12 clinical trials reported significant
reductions in FPG, HbA1c, body weight, and
Fig. 1 Initial reductions in FPG, HbA1c, and body weight
occurred before steady state exenatide concentrations were
reached. Geometric mean ± SE exenatide concentrations
(PK-evaluable population) and LS mean ± SE changes
from baseline (ITT population) in FPG, HbA1c, and body
weight. The PK threshold for FPG lowering with exenatide
QW (*50 pg/mL) is typically reached at *2 weeks [9].
FPG fasting plasma glucose, HbA1c glycated hemoglobin,
ITT intent-to-treat, LS least-squares, PK pharmacokinetic,
SE standard error
Table 2 Changes from baseline in FPG, HbA1c, and body weight in patients treated with exenatide QW with or without
nausea (intent-to-treat population)
Change in end point Patients with nausea (n5 18)a Patients without nausea (n5 111)b
FPG, mg/dL -32.5 ± 44.2 -31.5 ± 50.6
HbA1c, %c -1.3 ± 1.2 -1.4 ± 1.2
Body weight, kg -3.2 ± 3.5 -2.5 ± 3.5
Data are mean ± standard deviation
FPG fasting plasma glucose, HbA1c glycated hemoglobin, QW once weekly
a One patient had missing end point measures
b Four patients had missing end point measures
c Patients without nausea, baseline n = 110
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blood pressure as early as 2 weeks after initiating
treatment with exenatide QW, further
supporting an early onset of action [13]. In
this study, the time course of HbA1c change,
which is more gradual than FPG because it
depends on red blood cell turnover, was near
maximal 14 weeks after initiation of exenatide
QW. Changes in weight also occurred more
slowly than effects on FPG, as the physiology of
weight loss is more gradual than that of FPG
reductions.
It is important for physicians and patients to
understand the time course of AEs associated
with a long-acting medication. As shown in this
study, the majority of gastrointestinal AEs with
exenatide QW occurred early in therapy, after
the efficacy threshold but before steady state
was reached, and declined over time as
tolerance developed. A gradual increase in
exenatide concentrations, as occurs with
exenatide QW during microsphere dissolution,
has been associated with improved
gastrointestinal tolerability compared with
rapid dose escalation [14]. Similarly, pooled
analyses of randomized controlled trials found
that gastrointestinal AEs occurred less
frequently with exenatide QW (providing
continuous exenatide exposure) compared
with exenatide BID (providing intermittent
exenatide exposure), and decreased over time
[15, 16]. These analyses further support the
notion that the gradual increase in exenatide
concentration through the microspheres
enhances gastrointestinal tolerability.
While some physicians and patients seek to
avoid gastrointestinal AEs, others may believe
that nausea indicates response to therapy. Our
subanalysis results counter this belief, showing
Fig. 2 Relationship of the incidences of nausea and
vomiting (ITT population) with exenatide concentration
(geometric mean ± SE; PK-evaluable population). The
inset shows the incidences of nausea and vomiting on a
scale from 0% to 10%. ITT intent-to-treat, PK pharma-
cokinetic, SE standard error
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that improvements in glycemic control were
similar in patients with or without nausea
although weight loss may be slightly greater in
patients with nausea.
Limitations of this study include the small
number of patients and the post hoc nature of
the analysis; in particular, there were a small
number of patients with nausea in the
subanalysis and it was not powered to analyze
differences between patients with and without
nausea. In addition, the time course of clinical
responses and PK of exenatide QW were
evaluated in different although well-matched,
patient populations. This study also lacked
glycemic efficacy measures at earlier (1 or 2
week) time points because they were not
indicated in the protocol.
CONCLUSIONS
Although exenatide-containing microspheres
deliver exenatide via a gradual release
mechanism, exenatide QW resulted in prompt
treatment responses once the activity threshold
was reached, which occurred weeks before
steady state exenatide concentrations were
attained. Near-maximal improvements in FPG
and clinically relevant reductions in HbA1c
(-0.6%) occurred by week 4, followed by
weight loss. The occurrence of nausea and
vomiting declined over time, with tolerance
developing as exenatide reached steady state
concentrations.
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